Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058013 | 0.84 | CYP1A2 (0.56) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL2717077 | 0.84 | CYP1A2 (0.56) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL9186322 | 0.80 | CYP1A2 (0.52) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL24633577 | 0.77 | CYP1A2 (0.48) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL13739182 | 0.77 | CYP1A2 (0.48) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL13737910 | 0.77 | CYP1A2 (0.48) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL244649 | 0.77 | CYP1A2 (0.48) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL23797305 | 0.77 | CYP1A2 (0.48) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL10259445 | 0.76 | CYP1A2 (0.68) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL13737717 | 0.74 | CYP1A2 (0.46) | CYP1A2LMNAKDM4EPOLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101591291-A | The synthetic method of 2-ethenyl quinoline compound | INST MATERIA MEDICA CAMS (CN) | 2009-12-02 | — | — | CN | claimed |
| EP-2736885-B1 | QUINOLINE-, QUINOXALINE OR BENZOTHIAZOLE BASED CYSTEINYL LEUKOTRIENE ANTAGONISTS (LTC4) | SUN PHARMA ADVANCED RES CO LTD (IN) | 2020-03-25 | — | — | EP | disclosed |
| US-9102665-B2 | Cysteinyl leukotriene antagonists | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2015-08-11 | — | — | US | disclosed |
| US-20140155596-A1 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2014-06-05 | — | — | US | disclosed |
| EP-2736885-A2 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | Sun Pharma Advanced Research Company Ltd (IN) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013051024-A2 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-04-11 | — | — | WO | disclosed |
| CN-101591291-A | The synthetic method of 2-ethenyl quinoline compound | INST MATERIA MEDICA CAMS (CN) | 2009-12-02 | — | — | CN | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
| EP-1560834-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043966-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-05-27 | — | — | WO | disclosed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0685478-B1 | QUINOLINE DERIVATIVES | UBE INDUSTRIES (JP) | 2001-10-24 | — | — | EP | disclosed |
| CN-1046279-C | Quinoline derivative | UBE INDUSTRIES (JP) | 1999-11-10 | — | — | CN | disclosed |
| US-5591752-A | LEUKOTRIENE ANTAGONIST, ANTIALLERGEN, ANTIINFLAMMATORY AGENT, DIBENZ(B,E)OXEPINE | UBE INDUSTRIES, LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| CN-1117730-A | Quinoline derivative | UBE INDUSTRIES (JP) | 1996-02-28 | — | — | CN | disclosed |
| EP-0685478-A1 | QUINOLINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | CYP1A2 626/4885LMNA 4007/4885KDM4E 1356/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | CYP1A2 681/4885LMNA 2810/4885KDM4E 3264/4885 |
| US-20140155596-A1 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | LTC4S, CYSLTR2, CYSLTR1 | CYP1A2 1500/4885LMNA 1681/4885KDM4E 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.